Abbott's Q2 2026 Sales Soar 13%, Shares Jump 10.52%

By Philip Seaworth • Thursday, July 16 16:05 • Permanent Link

Abbott reported second-quarter 2026 sales of $12.593 billion, up 13.0% from a year earlier, as growth accelerated across diagnostics and medical devices and the company raised its full-year earnings outlook.

Adjusted diluted earnings per share rose to $1.31 in the quarter from a lower prior-year level, while GAAP diluted EPS was $0.53. For the first half, sales reached $23.757 billion, up 10.5% from the same period of 2025.

The strongest quarterly sales growth came from diagnostics, where revenue jumped 42.3% to $3.092 billion, driven by the inclusion of Exact Sciences and gains in core laboratory testing and cancer diagnostics. Core laboratory diagnostics sales increased 4.4% to $1.418 billion, while cancer diagnostics contributed $919 million. Rapid and molecular diagnostics fell 7.3% to $755 million.

Medical devices generated $5.853 billion in second-quarter sales, up 9.0%. Within that segment, electrophysiology rose 14.0% to $861 million, rhythm management increased 10.4% to $743 million, heart failure climbed 9.0% to $401 million, vascular rose 6.1% to $803 million, and diabetes care advanced 2.0% to $2.188 billion. Continuous glucose monitor sales in diabetes care increased 11.0%.

Established pharmaceuticals posted $1.499 billion in sales, up 8.4%, with key emerging markets growing 9.8% to $1.164 billion. Nutrition sales declined 3.1% to $2.144 billion, including a 10.7% drop in U.S. pediatric nutrition and a 6.4% decline in U.S. adult nutrition.

Geographically, U.S. sales rose 22.0% to $5.216 billion, while international sales increased 7.5% to $7.377 billion. For the first half, U.S. sales climbed 12.4% to $9.490 billion and international sales rose 9.3% to $14.267 billion.

Abbott returned $2.1 billion to shareholders in the quarter through dividends and share repurchases.

For the full year, Abbott reaffirmed comparable sales growth guidance of 6.5% to 7.5% and raised adjusted diluted EPS guidance to $5.45 to $5.60 from a prior range of $5.38 to $5.58. Third-quarter adjusted diluted EPS guidance was set at $1.38 to $1.46. Following these announcements, the company's shares moved 10.52%, and are now trading at a price of $98.665. For the full picture, make sure to review ABBOTT LABORATORIES's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.